NASDAQ · ZYME
Healthcare · Biotechnology
$30.13
Up+$0.81 (+2.69%)
Updated Nov 4, 2026, 10:11 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ZYME
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
ZYME closed at $30.13 after 21 trading sessions, up 17.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $29.41 | $30.40 | $29.20 | $30.13 | 2.52M |
| Nov 2, 2026 | $28.69 | $29.28 | $28.27 | $28.99 | 1.18M |
| Oct 30, 2026 | $28.81 | $29.015 | $28.26 | $28.61 | 2.88M |
| Oct 29, 2026 | $29.20 | $29.50 | $28.53 | $28.71 | 806.23K |
| Oct 28, 2026 | $28.54 | $29.465 | $28.54 | $28.90 | 833.16K |
| Oct 27, 2026 | $28.21 | $29.185 | $27.9567 | $28.85 | 1.13M |
| Oct 26, 2026 | $28.36 | $28.5861 | $27.5874 | $28.37 | 833.94K |
| Oct 23, 2026 | $28.77 | $28.77 | $27.28 | $28.22 | 1.12M |
| Oct 22, 2026 | $28.12 | $28.97 | $27.99 | $28.44 | 757.35K |
| Oct 21, 2026 | $26.96 | $28.27 | $26.90 | $28.115 | 1.32M |
| Oct 20, 2026 | $25.76 | $27.20 | $25.71 | $26.91 | 3.13M |
| Oct 19, 2026 | $25.06 | $25.745 | $25.06 | $25.54 | 2.04M |
| Oct 16, 2026 | $25.67 | $25.855 | $24.94 | $25.03 | 632.91K |
| Oct 15, 2026 | $25.19 | $26.21 | $25.18 | $25.75 | 751.93K |
| Oct 14, 2026 | $25.00 | $25.20 | $24.60 | $24.77 | 558.78K |
| Oct 13, 2026 | $25.04 | $25.60 | $24.915 | $25.07 | 2.46M |
| Oct 12, 2026 | $25.56 | $25.79 | $25.19 | $25.33 | 2.78M |
| Oct 9, 2026 | $25.28 | $26.34 | $25.28 | $25.79 | 491.14K |
| Oct 8, 2026 | $26.24 | $26.24 | $25.00 | $25.26 | 1.37M |
| Oct 7, 2026 | $25.75 | $27.02 | $25.17 | $26.53 | 1.62M |
| Oct 6, 2026 | $26.42 | $26.79 | $25.51 | $25.65 | 1.47M |
The latest Smart Investors Daily articles mentioning ZYME.
Company
Market Activity
Research & News
ZYME research
Company profile and research snapshot.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | Truist Securities | Buy | — |
| Oct 7, 2026 | Truist Securities | Buy | — |
| Sep 29, 2026 | Citigroup | Buy | — |
| Sep 17, 2026 | Wolfe Research | Outperform | — |
| Sep 3, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Nov 3, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology businesses offset product-specific pressures and continued investment in its pipeline. Chief Execu
SeekingAlpha · Oct 29, 2026
2026-10-29. The following slide deck was published by Zymeworks Inc.
Yahoo · Oct 29, 2026
Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga · Oct 28, 2026
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZYME.
